Recent work by Fleming researchers demonstrates that the histone methyltransferase Smyd3 is required for the development of experimentally induced liver and colon cancer in mice. Pubmed

The new study published in Cancer Cell by Sarris et al. shows that Smyd3 expression correlates with poor prognosis of human hepatocellular carcinoma. Smyd3 is identified as a novel “histone-code reader” protein, which invades active chromatin domains and potentiates the transcription of cancer-related genes. Smyd3 function is required for the activation of oncogenic pathways, cell proliferation and epithelial to mesenchymal transition during tumorigenesis. The results suggest that Smyd3 is a promising therapeutic target for liver and colon cancer. 

B.S.R.C. "Alexander Fleming"
34 Fleming Street, 16672 Vari, Greece
Contact us - Privacy Policy